Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
151-165 of 4442 results
Allergan exercises option to buy Motus Therapeutics
By PBR Staff Writer
Allergan has exercised its option to acquire Motus Therapeutics, a biopharmaceutical firm engaged in the development of peptide therapeutics to treat gastrointestinal (GI) diseases.
Drug Research > Drug Discovery & Development > News
Inositec secures $1.42m financing to advance new class of inositol hexaphosphate-based drug candidates
Inositec, which is engaged in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), has closed a CHF1.4m ($1.42m) seed financing.
Drug Research > Drug Discovery & Development > News
GSK partners with Fimbrion to develop UTI drug
By PBR Staff Writer
GlaxoSmithKline (GSK) has partnered with US life sciences firm Fimbrion Therapeutics for the development of a small molecule drug to treat prevent urinary tract infections (UTIs).
Drug Research > Drug Discovery & Development > News
Debiopharm reaches key development milestones for Staphylococcus-selective antibiotic Debio 1450
Debiopharm International has announced various significant achievements in the development of its new antibiotic Debio 1450, selectively active on staphylococcal species including hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA).
Drug Research > Drug Discovery & Development > News
NBE Therapeutics, Sotio partner to develop next-generation antibody-drug conjugates
NBE Therapeutics and Sotio have partnered to develop next-generation antibody-drug conjugates (ADCs) for improved cancer therapy.
Drug Research > Drug Discovery & Development > News
Redx Pharma identifies drug development candidate for leukaemia program
Redx Pharma has identified a drug development candidate for its reversible Bruton’s Tyrosine Kinase (BTK) inhibitor program.
Drug Research > Drug Discovery & Development > News
Sun Pharma, ICGEB partner to develop dengue vaccine
Drugmaker Sun Pharmaceutical Industries has partnered with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a new dengue vaccine.
Drug Research > Drug Discovery & Development > News
Domain Therapeutics creates new company to stop Parkinson’s disease progression
France-based biopharmaceutical firm Domain Therapeutics has established a new company, Mavalon Therapeutics, dedicated to develop a drug candidate to stop the progression of Parkinson’s disease.
Drug Research > Drug Discovery & Development > News
Antegrin and Cascadia merge to form Indalo Therapeutics
Antegrin Therapeutics and Cascadia Therapeutics have established Indalo Therapeutics, a biotechnology company dedicated to developing novel therapies to treat fibrotic diseases.
Drug Research > Drug Discovery & Development > News
Sofinnova closes latest venture capital fund at $650m
Biotech-focused investment company Sofinnova has closed Sofinnova Venture Partners X at its hard cap of $650m.
Drug Research > Drug Discovery & Development > News
TransThera raises $10m financing to develop Novel NCE Drugs
Biotech startup TransThera Biosciences has raised Round A Financing close to $10m from a group of investors, led by Morningside Ventures.
Drug Research > Drug Discovery & Development > News
AMAG Pharmaceuticals achieves key milestones in next generation development programs
AMAG Pharmaceuticals has achieved two key milestones in its next generation development programs for Makena and Feraheme.
Drug Research > Drug Discovery & Development > News
RXi Pharmaceuticals signs option deal to buy MirImmune
By PBR Staff Writer
RXi Pharmaceuticals has signed an option agreement to acquire MirImmune, a privately held biopharmaceutical firm engaged in the development of new generation immunotherapies for cancer.
Drug Research > Drug Discovery & Development > News
Metabrain Research and Medicxi establish Kymo Therapeutics
Metabrain Research has signed an agreement with Medicxi, an European life sciences venture capital firm, for the inception of Kymo Therapeutics, incorporated in Cambridge (UK).
Drug Research > Drug Discovery & Development > News
Alnylam scraps RNAi drug development over safety concerns
By PBR Staff Writer
Alnylam Pharmaceuticals is stopping the development of revusiran, a therapeutic intended at treating hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), due to safety concerns.
Drug Research > Drug Discovery & Development > News
151-165 of 4442 results